|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.59 - 32.92|
|52 Week Range||29.25 - 36.34|
|PE Ratio (TTM)||193.00|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.69|
QIAGEN N.V. today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
QIAGEN N.V. today announced the launch of QIAstat-Dx® in Europe, providing a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology and other diseases.
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2018 on Wednesday, May 2 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
QIAGEN N.V. today launched two novel liquid biopsy panels to evaluate circulating tumor cells in the growing field of research into molecular mechanisms in prostate and lung cancers.
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN N.V. announced today that its QuantiFERON-TB® Gold Plus , the gold standard in accurate, cost-effective testing for latent tuberculosis infection, has been endorsed for immigration medical screening by the International Panel Physicians Association .
Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS System. Natera's Constellation™ software would also be accessible for users of these and other assays in combination with the QIAGEN Clinical Insights (QCI) bioinformatics solution.
QIAGEN N.V. , a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. , a leading developer of next-generation sequencing assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.
QIAGEN N.V. today endorsed new guidelines issued by the World Health Organization , which coordinates global efforts to control tuberculosis , calling for harmonization of preventive screening and treatment of latent TB infection among vulnerable groups in countries with a high disease burden, as well as in low-burden countries.
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
QIAGEN N.V. announced today that it welcomed a decision by the U.S. Centers for Disease control to require the use of modern blood-based tests for tuberculosis screening.
Stock Monitor: National Research Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors.com has just released a free earnings report on QIAGEN N.V. (NYSE: QGEN ). If you ...
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
QIAGEN N.V. today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus as an in vitro diagnostic to detect tuberculosis infection.
QIAGEN N.V. today announced the European launch of its novel therascreen PITX2 RGQ PCR Kit, the first clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy.